In Brief: An Asenapine Patch (Secuado) for Schizophrenia

Date: January 11, 2021
Issue #: 
1615Summary: 
A transdermal formulation of the second-generation
(atypical) antipsychotic asenapine (Secuado– Noven)
has been approved by the FDA for once-daily treatment of
schizophrenia in adults. Asenapine is the first antipsychotic
to become available in a transdermal formulation in the US.
A twice-daily sublingual tablet formulation of asenapine(Saphris) has been available since 2009.

Source: The Medical Letter - July 23, 2020 Category: Drugs & Pharmacology Authors: admin Tags: Antipsychotics Asenapine Saphris Schizophrenia Secuado Source Type: research